AstraZeneca and Daiichi Sankyo have secured European Commission approval for Datroway (datopotamab deruxtecan) as a first-line monotherapy for adult patients diagnosed with unresectable or metastatic
The European Commission has officially granted marketing authorization for AbbVie’s RINVOQ (upadacitinib) for the treatment of severe alopecia areata in patients 12 years of age and older. This approv
Comments